FDA Outlines Considerations for Conducting Clinical Investigations Using Psychedelic Drugs
Hall Render
SEPTEMBER 15, 2023
In June 2023, the Food and Drug Administration (“FDA”) released Draft Guidance outlining its current view of the psychedelic research landscape. While the FDA does not define psychedelics, it indicated that the shorthand term “psychedelic” includes “classic psychedelics,” which are typically understood to be 5-HT2 agonists (e.g.,
Let's personalize your content